– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 –
– STRO-006, ITGB6-targeting ADC, enters clinic with first patient dosed; initial update expected second half of 2027 –
– STRO-227, Sutro’s PTK7-targeting dual-payload ADC, advancing toward clinical development early 2027 –
– Astellas dosed first patient in second dual-payload iADC program, triggering milestone payment to Sutro –
– Strong balance sheet with
“Over the past year, we have delivered on our commitment to advance our next-generation ADCs with two programs, STRO-004 and STRO-006, entering the clinic in less than a year, and our dual-payload ADC, STRO-227, expected to follow in early 2027,” said
Sutro Pipeline
STRO-004: Sutro’s potential best-in-class Tissue Factor (TF)-targeting DAR8 exatecan ADC is being evaluated in the ongoing Phase 1 STRIVE-01 study in patients with advanced solid tumors. As previously reported in
STRO-006: Sutro’s next-generation, highly selective integrin ß6 (ITGB6)-targeting ADC with a DAR8 exatecan payload, is designed for the treatment of multiple solid tumors. In
STRO-227: Sutro’s DAR10 dual-payload ADC targeting PTK7, consists of MMAE (DAR2) and exatecan (DAR8) payloads to enable complementary mechanisms of action within a single molecule. The program is advancing toward initiation of a Phase 1 clinical trial in early 2027 and is a key component of Sutro’s strategy to expand its portfolio of ADCs designed for the potential to widen the therapeutic index and overcome resistance.
Next-Generation ADC Collaborations
Astellas: Two programs are advancing in the clinic under Sutro’s collaboration with Astellas focused on dual-payload immunostimulatory ADCs (iADCs). The first program, which targets TROP2, continues to actively dose patients.
The second program, targeting B7-H3, began dosing patients, resulting in a
Recent Scientific Presentations
At the 17th Annual
Investor Conferences
Management will participate in the following upcoming healthcare investor conferences. Where available, live webcasts of the presentations can be accessed on the Events & Presentations page in the Investor Relations section of the Company’s website at www.sutrobio.com. Archived replays will remain available for at least 30 days following each event.
UBS Global Biopharma Conference
Fireside Chat Date/Time:
Location:
Jefferies Global Healthcare Conference
Fireside Chat Date/Time:
Location:
Piper Sandler 38th Annual Healthcare Conference?
Fireside Chat Date/Time:
Location:
Corporate Updates
In September, Sutro appointed
Third Quarter 2026 Financial Highlights
Cash,
As of
Revenue
Revenue was
Research & Development (R&D) and General & Administrative (G&A) Expenses
Total R&D and G&A expenses for the quarter ended
About Sutro Biopharma
Sutro Biopharma, Inc. is a clinical-stage biotechnology company advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities; timing of announcements of IND submissions, trial initiation, clinical results, and other regulatory filings; outcome of discussions with regulatory authorities; potential benefits, efficacy and safety profile of the Company’s product candidates and platform; potential business development and partnering transactions; potential market opportunities for the Company’s product candidates; the positioning of the Company’s product candidates in the competitive landscape; the timing and receipt of anticipated future milestone and royalty payments; and the Company’s expected cash runway. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the market size for the Company’s product candidates to be smaller than anticipated, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to obtain, maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and achieve development goals, the Company’s ability to protect intellectual property, the Company’s commercial collaborations with third parties, the impact of health pandemics, tariffs, regional geopolitical conflicts, changes in interest rates, inflation, potential uncertainty with respect to the debt ceiling and government shutdowns, and other risks and uncertainties described under the heading “Risk Factors” in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com
Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
Sutro Biopharma, Inc.
Selected Statements of Operations Financial Data
(Unaudited)
(In thousands, except share and per share amounts)
| Three Months Ended | |||||||||
| 2026 | 2025 | ||||||||
| Revenue | $ | 9,098 | $ | 9,693 | |||||
| Operating expenses | |||||||||
| Research and development | 23,499 | 39,853 | |||||||
| General and administrative | 7,539 | 8,741 | |||||||
| Restructuring and related costs | 16 | 9,558 | |||||||
| Total operating expenses | 31,054 | 58,152 | |||||||
| Loss from operations | (21,956 | ) | (48,459 | ) | |||||
| Interest income | 1,466 | 2,009 | |||||||
| Non-cash interest expense related to the sale of future royalties | (10,153 | ) | (9,670 | ) | |||||
| Interest and other income (expense), net | (846 | ) | (737 | ) | |||||
| Loss before provision for income taxes | (31,489 | ) | (56,857 | ) | |||||
| Provision for / (benefit) from income taxes | — | — | |||||||
| Net loss | $ | (31,489 | ) | $ | (56,857 | ) | |||
| Net loss per share, basic and diluted | $ | (1.90 | ) | $ | (6.66 | ) | |||
| Weighted-average shares used in computing basic and diluted loss per share | 16,583,806 | 8,540,708 | |||||||
Selected Balance Sheets Financial Data
(Unaudited)
(In thousands)
| 2026 (1) | 2025 (2) | |||||||
| Assets | ||||||||
| Cash, cash equivalents and marketable securities | $ | 142,177 | $ | 141,428 | ||||
| Accounts receivable | 12,815 | 3,977 | ||||||
| Property and equipment, net | 7,127 | 10,648 | ||||||
| Operating lease right-of-use assets | 7,180 | 10,903 | ||||||
| Other assets | 7,349 | 6,874 | ||||||
| Total Assets | $ | 176,648 | $ | 173,830 | ||||
| Liabilities and Stockholders’ Deficit | ||||||||
| Accounts payable, accrued expenses and other liabilities | $ | 40,122 | $ | 58,482 | ||||
| Deferred revenue | 10,054 | 12,590 | ||||||
| Operating lease liability | 9,700 | 15,674 | ||||||
| Deferred royalty obligation related to the sale of future royalties | 249,308 | 219,536 | ||||||
| Total liabilities | 309,184 | 306,282 | ||||||
| Total stockholders’ deficit | (132,536 | ) | (132,452 | ) | ||||
| Total Liabilities and Stockholders’ Deficit | $ | 176,648 | $ | 173,830 | ||||
(1)The condensed balance sheet as of
(2) The condensed balance sheet as of
Source: